In today’s compressed-margin industrial environment, Operational Excellence (OpEx) is not an optional corporate initiative; it is a fundamental survival mechanism. Companies facing inflationary supply chain pressures, skyrocketing labor costs, and aggressive private equity holding periods must relentlessly strip waste from their processes and optimize their working capital. However, many organizations that invest millions into Lean […]
Author Archives: Jeremy Gleason
The biotechnology and pharmaceutical industries rely on clinical operations leaders to perform one of the most complex, high-stakes translations in modern science: turning a brilliant biological hypothesis into a rigorously executed, regulatory-compliant human clinical trial. A billion-dollar molecule or breakthrough cell therapy is commercially worthless without the pristine clinical data required to prove its safety […]
Furniture and home goods brands operate at the intersection of product design, consumer preferences, manufacturing, sourcing, retail, and digital commerce. To grow sustainably, these businesses need executive leaders who can protect margins, manage inventory, develop compelling products, strengthen distribution, and respond to changing customer expectations. Hiring the right executive requires more than finding a leader […]
Across manufacturing, supply chain, and complex industrial operations, continuous improvement is no longer a theoretical exercise—it is a mandatory survival strategy. In an era defined by extreme margin compression, volatile supply chains, and severe skilled labor shortages, organizations must ruthlessly eliminate operational waste to protect their bottom line. However, the corporate landscape is littered with […]
Hiring drug delivery systems executives requires a careful assessment of technical depth, cross-functional leadership, regulatory awareness, and commercial judgment. Whether an organization is developing an autoinjector, inhalation platform, wearable delivery device, injectable system, or another drug-device combination, its leadership team must connect formulation science, device engineering, manufacturing readiness, and product commercialization. For companies preparing to […]
The clinical research industry is navigating an era of unprecedented complexity. Clinical trial protocols have become exponentially more sophisticated, targeting rare diseases, genetically defined patient populations, and leveraging novel modalities like cell and gene therapies (CGT) and mRNA. Simultaneously, the operational mechanics of trials have evolved, integrating Decentralized Clinical Trials (DCTs), complex global supply chains, […]
Aerospace and defense organizations depend on experienced leaders who can translate complex engineering requirements into reliable production, manage demanding programs, and coordinate teams across highly specialized operating environments. As companies pursue new contracts, expand manufacturing capacity, modernize existing systems, and invest in advanced technologies, securing the right executive talent becomes an important part of business […]
Bringing a surgical robotics platform to market is a monumental achievement, but commercial success is never guaranteed by technical brilliance alone. The transition from a functional prototype to a globally adopted clinical standard requires an executive leadership team capable of orchestrating a vast, interconnected ecosystem. A brilliant mechatronic architecture means nothing if the system lacks […]
In the biotechnology sector, brilliant science is only the starting point. The journey from benchtop discovery to an FDA-approved, commercially viable therapy is one of the most capital-intensive, highly regulated, and binary endeavors in the global economy. A single asset can require hundreds of millions of dollars and a decade of clinical trials to reach […]
The biotechnology industry is uniquely unforgiving. Unlike traditional software startups where companies can pivot on a weekly basis, a biotech company’s trajectory is defined by decade-long timelines, hundreds of millions of dollars in capital expenditure, and the binary outcomes of FDA regulatory approvals. In this high-stakes environment, the most critical variable predicting success or failure […]










